カルナバイオサイエンスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2018/04/11 | 1,474 | 1,499 | 1,422 | 1,429 | -12 | -0.8% | 222,000 |
| 2018/04/10 | 1,467 | 1,516 | 1,436 | 1,441 | -16 | -1.1% | 351,000 |
| 2018/04/09 | 1,456 | 1,490 | 1,415 | 1,457 | -13 | -0.9% | 263,400 |
| 2018/04/06 | 1,488 | 1,514 | 1,436 | 1,470 | -18 | -1.2% | 512,300 |
| 2018/04/05 | 1,551 | 1,568 | 1,461 | 1,488 | -49 | -3.2% | 937,400 |
| 2018/04/04 | 1,623 | 1,628 | 1,530 | 1,537 | -84 | -5.2% | 790,600 |
| 2018/04/03 | 1,720 | 1,735 | 1,601 | 1,621 | -59 | -3.5% | 835,300 |
| 2018/04/02 | 1,845 | 1,880 | 1,661 | 1,680 | -153 | -8.3% | 1,061,200 |
| 2018/03/30 | 1,810 | 1,909 | 1,706 | 1,833 | -17 | -0.9% | 1,905,100 |
| 2018/03/29 | 1,900 | 1,910 | 1,753 | 1,850 | +335 | +22.1% | 2,927,600 |
| 2018/03/28 | 1,515 | 1,515 | 1,515 | 1,515 | +300 | +24.7% | 69,300 |
| 2018/03/27 | 1,230 | 1,247 | 1,202 | 1,215 | -4 | -0.3% | 43,600 |
| 2018/03/26 | 1,205 | 1,221 | 1,157 | 1,219 | +15 | +1.2% | 60,900 |
| 2018/03/23 | 1,246 | 1,280 | 1,202 | 1,204 | -93 | -7.2% | 77,500 |
| 2018/03/22 | 1,299 | 1,310 | 1,286 | 1,297 | -2 | -0.2% | 22,300 |
| 2018/03/20 | 1,281 | 1,306 | 1,280 | 1,299 | -26 | -2% | 52,100 |
| 2018/03/19 | 1,331 | 1,332 | 1,282 | 1,325 | -9 | -0.7% | 60,400 |
| 2018/03/16 | 1,353 | 1,362 | 1,326 | 1,334 | -23 | -1.7% | 65,300 |
| 2018/03/15 | 1,372 | 1,376 | 1,337 | 1,357 | -15 | -1.1% | 93,400 |
| 2018/03/14 | 1,304 | 1,378 | 1,304 | 1,372 | +60 | +4.6% | 127,500 |
| 2018/03/13 | 1,278 | 1,329 | 1,278 | 1,312 | +22 | +1.7% | 51,800 |
| 2018/03/12 | 1,315 | 1,323 | 1,272 | 1,290 | -21 | -1.6% | 50,400 |
| 2018/03/09 | 1,323 | 1,352 | 1,305 | 1,311 | ±0 | ±0% | 70,000 |
| 2018/03/08 | 1,300 | 1,344 | 1,300 | 1,311 | +29 | +2.3% | 74,500 |
| 2018/03/07 | 1,290 | 1,313 | 1,257 | 1,282 | +9 | +0.7% | 71,900 |
| 2018/03/06 | 1,239 | 1,285 | 1,238 | 1,273 | +63 | +5.2% | 57,900 |
| 2018/03/05 | 1,295 | 1,307 | 1,204 | 1,210 | -80 | -6.2% | 92,600 |
| 2018/03/02 | 1,281 | 1,299 | 1,266 | 1,290 | -26 | -2% | 79,700 |
| 2018/03/01 | 1,287 | 1,319 | 1,265 | 1,316 | +7 | +0.5% | 84,000 |
| 2018/02/28 | 1,270 | 1,330 | 1,263 | 1,309 | +76 | +6.2% | 163,700 |
| 2018/02/27 | 1,290 | 1,293 | 1,232 | 1,233 | -37 | -2.9% | 85,200 |
| 2018/02/26 | 1,233 | 1,277 | 1,217 | 1,270 | +59 | +4.9% | 91,500 |
| 2018/02/23 | 1,216 | 1,230 | 1,199 | 1,211 | +9 | +0.7% | 24,800 |
| 2018/02/22 | 1,224 | 1,224 | 1,170 | 1,202 | -28 | -2.3% | 65,700 |
| 2018/02/21 | 1,198 | 1,241 | 1,186 | 1,230 | +34 | +2.8% | 86,400 |
| 2018/02/20 | 1,171 | 1,199 | 1,164 | 1,196 | +5 | +0.4% | 36,300 |
| 2018/02/19 | 1,184 | 1,199 | 1,175 | 1,191 | +37 | +3.2% | 47,900 |
| 2018/02/16 | 1,159 | 1,175 | 1,135 | 1,154 | +24 | +2.1% | 50,800 |
| 2018/02/15 | 1,116 | 1,151 | 1,103 | 1,130 | +1 | +0.1% | 67,200 |
| 2018/02/14 | 1,160 | 1,194 | 1,102 | 1,129 | -27 | -2.3% | 69,500 |
| 2018/02/13 | 1,205 | 1,221 | 1,138 | 1,156 | -38 | -3.2% | 128,600 |
| 2018/02/09 | 1,127 | 1,209 | 1,120 | 1,194 | -23 | -1.9% | 83,700 |
| 2018/02/08 | 1,194 | 1,224 | 1,155 | 1,217 | +67 | +5.8% | 100,500 |
| 2018/02/07 | 1,195 | 1,206 | 1,150 | 1,150 | +35 | +3.1% | 107,500 |
| 2018/02/06 | 1,110 | 1,160 | 1,064 | 1,115 | -126 | -10.2% | 274,700 |
| 2018/02/05 | 1,295 | 1,312 | 1,240 | 1,241 | -103 | -7.7% | 185,900 |
| 2018/02/02 | 1,328 | 1,344 | 1,313 | 1,344 | +14 | +1.1% | 45,000 |
| 2018/02/01 | 1,300 | 1,333 | 1,288 | 1,330 | +38 | +2.9% | 82,800 |
| 2018/01/31 | 1,287 | 1,305 | 1,265 | 1,292 | +7 | +0.5% | 56,300 |
| 2018/01/30 | 1,316 | 1,324 | 1,274 | 1,285 | -37 | -2.8% | 110,400 |
1751～
1800
件表示中 / 3720件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| カルナバイオ | 34,100円 | +13.5% | - | 0.00% | - | 2.63倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ノイルイミューン | 16,900円 | -28.6% | - | 0.00% | - | 1.55倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| クリングル | 100,300円 | +240.0% | - | 0.00% | - | 4.33倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
| モダリス | 9,300円 | - | - | 0.00% | - | 1.98倍 |
|
遺伝子治療薬の創薬ベンチャー、ＤＮＡ切断しないエピゲノム編集に強み。研究開発中心は米国 |
| ソレイジア | 3,000円 | +311.4% | - | 0.00% | - | 5.69倍 |
|
がん柱の創薬ベンチャー。候補品導入後に開発進め権利再導出、製品販売を行うビジネスモデル |
市場注目の銘柄
チャート関連のコラム
